Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Gemcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 2/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.60 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.60 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | CDA | P32320 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine SCHEMBL19235640 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL13262185 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12737233 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL19526092 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6761683 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL17858716 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12503065 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL249738 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL20827751 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL9143689 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| EP-3015137-B1 | ANTICANCER AGENT DECOMPOSITION METHOD AND ANTICANCER AGENT DECOMPOSITION DEVICE | TAMURA TECO CO LTD (JP) | 2022-10-26 | — | — | EP | claimed |
| EP-2578231-B1 | ANTITUMOR T CELL RESPONSE ENHANCER | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2022-10-26 | — | — | EP | claimed |
| WO-2025043036-A2 | 5-HALOURACIL-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS AND THEIR USE IN THETREATMENT OF CANCER | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240158794-A1 | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | SIRNAOMICS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-20230285364-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | SERVIER PHARMACEUTICALS LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-03 | — | — | US | disclosed |
| US-11707410-B2 | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients | CORNING INCORPORATED (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230173079-A1 | Conjugate Molecules | DIVERSE BIOTECH, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230173079-A1 | Conjugate Molecules | DIVERSE BIOTECH, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20070238865-A1 | intermediates in preparation of gemcitabine in large scale; reducing 1-oxoribose compound to obtain actol compound, reacting with halophosphate compound in presence of base to obtain a 1-phosphate furanose derivative, reacting with halide source, then crystallizing | HANMI PHARM CO., LTD (KR) | 2007-10-11 | — | — | US | disclosed |
| US-20070197473-A1 | Methods of using SAHA and Bortezomib for treating cancer | MERCK & CO., INC. | 2007-08-23 | — | — | US | disclosed |
| US-5464826-A | Antitumor, anticarcinogenic agents, treatment of herpes | ELI LILLY AND COMPANY (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0184365-B1 | IMPROVEMENTS IN THE TREATMENT OF TUMORS IN MAMMALS | ELI LILLY AND COMPANY (US) | 1993-08-04 | — | — | EP | disclosed |
| US-5118820-A | Carbohydrate is chemical intermediate for nucleoside | ELI LILLY AND COMPANY (US) | 1992-06-02 | — | — | US | disclosed |
| US-5061793-A | Antitumor agents | ELI LILLY AND COMPANY (US) | 1991-10-29 | — | — | US | disclosed |
| US-5015743-A | 2-Deoxy-2,2-difluororibose | ELI LILLY AND COMPANY (US) | 1991-05-14 | — | — | US | disclosed |
| US-4808614-A | Difluoro antivirals and intermediate therefor | ELI LILLY AND COMPANY (US) | 1989-02-28 | — | — | US | disclosed |
| US-4692434-A | NUCLEOSIDES | ELI LILLY AND COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285364-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | DHODH, DPYD, DLD | POLA1 881/4885PDE3A 1723/4885PDE4D 1951/4885 |
| US-20070197473-A1 | Methods of using SAHA and Bortezomib for treating cancer | HDAC5, HDAC6, HDAC4 | POLA1 1316/4885PDE3A 2997/4885PDE4D 2934/4885 |
| US-20240158794-A1 | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | ADAR, SAMHD1, RNASE1 | POLA1 105/4885PDE3A 3274/4885PDE4D 3094/4885 |
| US-11707410-B2 | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients | GCG, GLMN, GMNN | POLA1 1694/4885PDE3A 1689/4885PDE4D 2783/4885 |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | POLA1 288/4885PDE3A 282/4885PDE4D 292/4885 |
| US-20070238865-A1 | intermediates in preparation of gemcitabine in large scale; reducing 1-oxoribose compound to obtain actol compound, reacting with halophosphate compound in presence of base to obtain a 1-phosphate furanose derivative, reacting with halide source, then crystallizing | DCTPP1, NUDT1, TYMP | POLA1 100/4885PDE3A 4264/4885PDE4D 3412/4885 |
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | TYMP, ADA, CDA | POLA1 539/4885PDE3A 2888/4885PDE4D 2050/4885 |
| US-20230173079-A1 | Conjugate Molecules | CNR2, CNR1, MAG | POLA1 4289/4885PDE3A 4385/4885PDE4D 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.